KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Ionis Pharmaceuticals (IONS) over the last 13 years, with Q3 2025 value amounting to $110.7 million.

  • Ionis Pharmaceuticals' Change in Accured Expenses rose 95059.77% to $110.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.4 million, marking a year-over-year increase of 41996.17%. This contributed to the annual value of -$43.0 million for FY2024, which is 33178.07% down from last year.
  • Ionis Pharmaceuticals' Change in Accured Expenses amounted to $110.7 million in Q3 2025, which was up 95059.77% from $20.0 million recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Change in Accured Expenses registered a high of $110.7 million during Q3 2025, and its lowest value of -$46.2 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $2.1 million (2021), whereas its average is $4.4 million.
  • The largest annual percentage gain for Ionis Pharmaceuticals' Change in Accured Expenses in the last 5 years was 693388.95% (2022), contrasted with its biggest fall of 42921.83% (2022).
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Change in Accured Expenses stood at $6.5 million in 2021, then rose by 29.92% to $8.4 million in 2022, then soared by 407.21% to $42.8 million in 2023, then plummeted by 133.51% to -$14.3 million in 2024, then surged by 872.63% to $110.7 million in 2025.
  • Its Change in Accured Expenses was $110.7 million in Q3 2025, compared to $20.0 million in Q2 2025 and -$43.0 million in Q1 2025.